THERAPY DOSSIER · th-955d0e1181dd

E-52862 (selective sigma-1 receptor antagonist)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: S1RA; MR309
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06574360 ↗PHASE2recruiting

Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia (S1RA)

Schizophrenia

Enrolment: 90 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27087602 ↗2016Reported benefit

The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats.

RatOtherSprague-Dawley (infraorbital nerve and oxaliplatin models); Wistar (streptozotocin model)MaleIntraperitoneal20, 40 or 80 mg/kgDay 25 after infraorbital nerve constriction; from day 21 after streptozotocin;…

Model: Chronic constriction injury of the infraorbital nerve; streptozotocin-induced diabetic polyneuropathy; oxaliplatin-induced polyneuropathy

E-52862 dose-dependently reduced mechanical allodynia, mechanical hyperalgesia and cold allodynia across the three models, with increased rather than diminished effect after 7 days of twice-daily dosing.

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…